A prospective case-control study of 150 participants found circulating cell-free DNA distinguished ovarian cancer from benign ...
The University of Cambridge’s vet school is offering clinicians free PCR-based testing for suspected canine transmissible ...
Dr. Rick Baehner, Abbott’s chief medical officer for precision oncology, spoke to MedTech Dive about how the new version of the Oncodetect test performs and the market it addresses.
NeoCOAST-2 trial finds early ctDNA clearance in blood tests linked to improved lung cancer outcomes, potentially guiding ...
A new blood test could detect lung cancer recurrence months before it appears on scans, potentially enabling earlier ...
The growing role of Molecular Residual Disease (MRD) testing in cancer diagnosis and monitoring will be the focus of an ...
A new blood test could detect lung cancer recurrence months before it appears on scans, potentially enabling earlier ...
Foundation Medicine, Inc., a precision medicine company transforming lives in cancer care and beyond, today announced that ...
New findings suggest that a blood test can detect circulating tumor DNA (ctDNA), potentially identifying signs of lung cancer ...
Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers. Across many disease ...
On Friday, Abbott ( ABT) said its whole-genome sequencing-based Oncodetect test showed a 30-percentage-point improvement in sensitivity for colorectal cancer recurrence within two years of surgery ...
In 279 patients, one post-surgery draw yielded 72.2% sensitivity with whole-genome sequencing vs. 42.2% with exome sequencing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results